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Sildenafil Stops Progressive Chamber, Cellular,
and Molecular Remodeling and Improves Calcium
Handling and Function in Hearts With Pre-Existing
Advanced Hypertrophy Caused by Pressure Overload
Takahiro Nagayama, PHD,* Steven Hsu, BA,* Manling Zhang, MD, PHD,*
Norimichi Koitabashi, MD, PHD,* Djahida Bedja, MS,† Kathleen L. Gabrielson, PHD,†
Eiki Takimoto, MD, PHD,* David A. Kass, MD*
Baltimore, Maryland
Objective This study sought to test the efficacy of phosphodiesterase type 5A (PDE5A) inhibition for treating advanced hy-
pertrophy/remodeling caused by pressure overload, and to elucidate cellular and molecular mechanisms for this
response.
Background Sildenafil (SIL) inhibits cyclic guanosine monophosphate–specific PDE5A and can blunt the evolution of cardiac
hypertrophy and dysfunction in mice subjected to pressure overload. Whether and how it ameliorates more es-
tablished advanced disease and dysfunction is unknown.
Methods Mice were subjected to transverse aortic constriction (TAC) for 3 weeks to establish hypertrophy/dilation, and
subsequently treated with SIL (100 mg/kg/day) or placebo for 6 weeks of additional TAC.
Results The SIL arrested further progressive chamber dilation, dysfunction, fibrosis, and molecular remodeling, increas-
ing myocardial protein kinase G activity. Isolated myocytes from TAC-SIL hearts showed greater sarcomere short-
ening and relaxation, and enhanced Ca2 transients and decay compared with nontreated TAC hearts. The SIL
treatment restored gene and protein expression of sarcoplasmic reticulum Ca2 uptake adenosine triphos-
phatase (SERCA2a), phospholamban (PLB), and increased PLB phosphorylation (S16), consistent with improved
calcium handling. The phosphatase calcineurin (Cn) and/or protein kinase C- (PKC) can both lower phosphory-
lated phospholamban and depress myocyte calcium cycling. The Cn expression and PKC activation (outer
membrane translocation) were enhanced by chronic TAC and reduced by SIL treatment. Expression of PKC and
PKC also increased with TAC but were unaltered by SIL treatment.
Conclusions SIL treatment applied to well-established hypertrophic cardiac disease can prevent further cardiac and myocyte
dysfunction and progressive remodeling. This is associated with improved calcium cycling, and reduction of Cn
and PKC activation may be important to this improvement. (J Am Coll Cardiol 2009;53:207–15) © 2009 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.069t
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peart failure is a leading cause of morbidity and mortality
orldwide, commanding a large share of health care re-
ources, and despite recent advances, better treatment op-
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Manuscript received March 18, 2008; revised manuscript received July 2, 2008,
ccepted August 11, 2008.ions remain sorely needed (1). Hypertension and corre-
ponding hypertrophic heart disease are major risk factors
or heart failure, and the therapeutic suppression of hyper-
rophy is associated with improved mortality (2,3). To date,
See page 216
reatments designed to blunt hypertrophic remodeling and
elated dysfunction have largely focused on reducing vascu-
ar load and neurohormone stimulation. However, intracel-
ular pathways are also now being targeted, which may
rovide potent benefits by interfering with strategic nodes in
ore distal signaling processes (1,4).
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Sildenafil and Advanced Hypertrophic Heart Disease January 13, 2009:207–15An intriguing approach that
first arose somewhat as a surprise is
the inhibition of cyclic guanosine
monophosphate (cGMP)–specific
phosphodiesterase 5A (PDE5A)
by compounds such as sildenafil
(SIL). Such drugs are widely used
to treat erectile dysfunction, and
have long been thought to have
little role in the heart. However,
growing evidence supports cardiac
expression and functionality of
PDE5A (5) physiological effects
from its inhibitors. For example,
PDE5A inhibition can improve
ischemic cardiomyopathy (6),
doxorubicin toxicity (7), and pres-
sure overload–induced hypertro-
phy (8), all thought to be coupled
to enhanced protein kinase G ac-
tivation (9,10). Clinical studies of
SIL in heart failure patients have
reported improved exercise capac-
ty coupled to reduced pulmonary vascular resistance and better
ndothelial function (11,12). Based on such findings, the
ational Institutes of Health recently initiated a multicenter
linical trial of SIL for the treatment of heart failure with a
reserved ejection fraction (Clinical Trials.gov identifier:
CT00763867).
We previously reported that SIL exerts antihypertro-
hic effects against pressure overload when the treatment
s initiated at the onset of the stress or shortly (1 week)
hereafter (8). In the latter case, hearts first developed
oncentric hypertrophy with no dilation, and then im-
roved with treatment. However, it is unknown whether
IL can ameliorate more advanced disease, a nontrivial
uestion because PDE5A modulation seems to target
itric oxide– derived cGMP (9,10,13) and nitric oxide
ynthase (NOS) activity declines with sustained pressure
verload (14). Furthermore, the mechanisms of SIL-
mproved cardiac function in pressure overload hearts (8)
nd whether they apply to more advanced disease remain
nknown. Accordingly, the present study tested the
fficacy of delayed SIL treatment of hearts subjected to
ressure overload. We show evidence of chamber, cellu-
ar, and molecular benefits of PDE5A inhibition in
dvanced disease, and reveal novel mechanisms for func-
ional improvement related to calcium cycling and its
olecular modulation.
ethods
nimal models. Male C57Bl/6 mice (age 9 to 12 weeks,
ackson Labs, Bar Harbor, Maine) were used. Pressure
verload was produced by transverse aortic constriction
Abbreviations
and Acronyms
cGMP  cyclic guanosine
monophosphate
Cn  calcineurin
ISO  isoproterenol
LV  left ventricular
NOS  nitric oxide
synthase
PDE5A 
phosphodiesterase 5A
PKC  protein kinase C-
PKG  protein kinase G
SERCA 2a  sarcoplasmic
reticulum Ca2 adenosine
triphosphatase
SIL  sildenafil
SR  sarcoplasmic
reticulum
TAC  transverse aortic
constrictionTAC) (8), with shams undergoing the same operation cithout aortic constriction. Oral SIL (100 mg/kg/day) was
rovided in soft diet (Transgenic Dough Diet, Bio-Serv,
renchtown, New Jersey) (8) starting on week 4 after TAC
nd continuing for 5 additional weeks. Although this dose is
igh for humans, the mouse metabolizes SIL at a higher
ate (15), and this dose yields a free plasma concentration of
0 to 15 nM, within the specific and therapeutic range for
DE5A (8). Control data for chronic SIL only have been
reviously reported (8), and the effects were found to be
egligible. The Johns Hopkins University Animal Care and
se Committee approved the protocol.
hysiological studies. Cardiac function was assessed by
ransthoracic echocardiography in conscious mice (Acu-
on Sequoia C256, Siemens Inc., New York, New York)
sing a 15-MHz linear-array transducer, and by invasive
ressure-volume analysis using the conductance catheter
ethod (SPR-839, Millar Instruments, Inc., Houston,
exas). The catheter was inserted via the left ventricular
LV) apex in open-chest, anesthetized mice, and posi-
ioned along the long axis as described (8).
istology. Formalin (10%)-fixed, paraffin-embedded LV
yocardium was sectioned (5 m) and stained with
ematoxylin-eosin or picrosirius red. Myocyte diameter and
nterstitial and perivascular collagen fraction were determined
y digital image analysis (Photoshop version 7.0, Adobe
ystems, San Jose, California; Image J, version 1.41, NIH,
ethesda, Maryland), with the observer blinded as to tissue
ource. Four different hearts in each group, with 5 separate
elds of cells (total 50 to 70 cells for each heart) were analyzed.
solated myocyte physiologic studies. Sarcomere short-
ning (Myocam, IonOptix, Milton, Massachusetts) and
hole-cell Ca2 transient (Fura-2 AM mol/l, Invitro-
en, Carlsbad, California) was assessed in freshly isolated
dult cardiomyocytes (4 hearts per group) at 27°C using
.5-Hz field stimulation (15 to 20 cells from each heart)
s previously described (10). Although lower tempera-
ures can depress adrenergic modulation, we have shown
arked concordance of adrenergic regulation by PDE5A
nhibitors under various conditions between such in vitro
onditions and in vivo hearts (9,10). Data at rest and after
soproterenol (ISO) (10 nmol/l) stimulation were obtained.
rotein and gene expression. Protein and messenger
ibonucleic acid (mRNA) isolates were prepared from LV
issue flash frozen in liquid nitrogen, and expression was
ssessed using standard techniques (Online Appendix).
mmunofluorescent histology. Protein kinase C- (PKC)
yocyte localization was examined with antisera by confocal
uorescent immunohistochemistry as described (10) (Online
ppendix).
tatistical analysis. Data are presented as mean  SEM.
ifferences between groups were assessed by 1- or 2-way
nalysis of variance (with or without repeated measures, as
equired) followed by a Tukey multiple comparisons test. In
nstances in which within-group variance differed substan-
ially, a nonparametric Kruskal-Wallis test and Bonferroni
orrection was used.
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January 13, 2009:207–15 Sildenafil and Advanced Hypertrophic Heart Diseaseesults
IL inhibits progressive hypertrophy and dilation in
ice subjected to TAC. After 3-week TAC, hearts had a
135% increase in LV mass, chamber end-systolic (91%)
nd end-diastolic (10%) dimensions, and reduced frac-
ional shortening (42%) (Fig. 1A). Subsequent treatment
ith SIL fully arrested progressive remodeling, whereas
ontrol hearts further dilated and hypertrophied after
-week TAC. Post-mortem analysis confirmed that both
eart and lung weight, normalized to tibia length, was lower
ith SIL treatment (Fig. 1B). Myocyte cross-sectional
imension and interstitial and perivascular fibrosis was also
educed in SIL-treated myocardium (Fig. 1C).
A- and B-type natriuretic peptide gene expression increased
arkedly after 3-week TAC. Both increased 30% to 50% after
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Figure 1 Delayed Sildenafil Treatment Suppresses Progressive
Dysfunction, Fibrosis, and Hypertrophy in Hearts Subje
(A) Representative echocardiographic images and summary analysis in sham cont
treatment (dSIL). The p values are for 2-way analysis of variance (ANOVA); first val
group comparisons (Tukey test) are denoted by symbols: *p  0.05 versus 9W TA
weight normalized by tibial length (TL). *p  0.0001 versus sham. †p  0.007 ve
and eosin (HE) and picrosirius red (PSR) showing reduced interstitial and perivasc
panel. *p  0.01 versus sham and 9W TAC  SIL. ‡p  0.01 versus sham. ‡p 
 left ventricular systolic diastolic dimension; LVDs  left ventricular systolic dime-week TAC in nontreated hearts but remained at 3-week
evels in those receiving SIL (Fig. 2A). -myosin heavy chain
lso increased, but this was not reduced in SIL-treated hearts.
odulation of protein kinase G (PKG) activity and fetal
ene expression. We next assessed the activation of
GMP-stimulated PKG in hearts with or without delayed
IL treatment. Enzyme activity assessed by S-239-
asodilator-stimulated phosphoprotein phosphorylation and
n vitro kinase assay both showed increases after 9-week
AC that were further enhanced in SIL-treated animals
Fig. 2B). TAC resulted in increased PKG-1 (primary
ardiac isoform) protein expression (Fig. 2C), but this
eclined to normal levels with SIL treatment, supporting
ost-translational (cGMP stimulation) mechanisms in this
etting. The PDE5A protein expression was unaltered
mong the various conditions.
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Sildenafil and Advanced Hypertrophic Heart Disease January 13, 2009:207–15IL treatment improves cardiac contractility and relax-
tion in vivo and in vitro. Figure 3A shows the results of
V pressure-volume analyses. After 3-week TAC, hearts
ilated and had increased end-systolic elastance and contrac-
ility (dP/dtmax/IP and maximal power index), as reported in
umans with hypertrophic heart disease (16). More sustained
AC reduced contractility and prolonged relaxation in un-
reated hearts, but this was prevented by SIL.
To identify mechanisms for improved cardiac function,
V myocytes were studied (Fig. 3B). Compared with sham
ontrols, 9-week TAC myocytes had depressed sarcomere
hortening and prolonged relaxation, and SIL treatment
estored both to control levels. These changes were accom-
anied by improved calcium handling. The peak Ca2-
ransient was not significantly altered after 9-week TAC,
ut the time for 50% decline was prolonged. The latter
mproved toward control values with SIL treatment,
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blots of phospho-VASP protein expression (summary data to right) and in vitro PKG
(C) Western blot of PKG-1 and PDE5A protein expression (summary data to right
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pVASP  phosphorylated vasodilator-stimulating phosphoprotein; other abbrevihereas peak amplitude increased. Contraction, relaxation, cnd Ca2-transients all improved similarly with ISO in each
roup (p value for interaction by 2-way analysis of variance
ange: 0.2 to 0.94); thus, this cascade was not differentially
ffected by SIL treatment.
IL treatment modifies sarcoplasmic reticulum (SR) Ca2
andling protein expression and phosphorylation. Because
a2 cycling improved in SIL-treated TAC hearts, we
xamined SR handling proteins that might be modified by
he therapy. Gene expression of SR-Ca2 adenosine
riphosphatase (SERCA2a) and phospholamban declined
fter 3-week TAC (Fig. 4A), and this persisted after 9-week
AC. Protein expression was decreased at this time as well.
he SIL treatment increased both SERCA2a and phospho-
amban expression, and enhanced PLB s-23 phosphoryla-
ion (increasing Ca2-uptake) in comparison with non-
reated TAC.
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January 13, 2009:207–15 Sildenafil and Advanced Hypertrophic Heart Diseasenhanced PKG activity, but it could also result from
uppressed phosphatase activity. One mechanism involves
alcineurin (Cn), which inhibits protein phosphatase
nhibitor-1 activity, resulting in the disinhibition of the
hosphatase protein phosphatase-1 to lower PLB phos-
horylation (17,18). Cn protein expression and activity
indexed by regulator of calcineurin 1 mRNA) increased
fter 3-week TAC by 3.2-fold and 2.5-fold, respectively
both p  0.01) (Online Fig. 1), and remained elevated at
-week TAC in nontreated hearts but declined with SIL
Fig. 4C). Another mechanism for I-1 inactivation is its
hosphorylation by PKC at S67 and T75, which also
nhances PP1 activity and thus PLB dephosphorylation
19). PKC (and  and  isoforms) protein expression
ncreased markedly after 9-week TAC (Fig. 4D), and SIL
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Figure 3 Delayed Sildenafil Treatment in Hearts Subjected to P
Cardiac Systolic and Diastolic Function, Myocyte Sho
(A) Representative in vivo pressure-volume loops and summary analysis. The 3-we
tility (dP/dtmax) normalized to instantaneous developed pressure; peak power divid
declined and relaxation prolonged to levels at or below control after 9W TAC, and
deterioration; p value in each panel shows ANOVA result or for end-systolic elasta
†p  0.06 versus 9W TAC. ‡p  0.04 versus sham. ¶p  0.1 versus 9W TAC an
0.001 versus 3W TAC and 9W TAC  SIL. (B) Isolated myocyte sarcomere shorte
measured at rest and in response to isoproterenol (ISO) stimulation (n  4 hearts
p  0.001 for ISO and for group effect, p  0.2 for interaction effect for all param
 0.02 versus 9W TAC. ¶p  0.001 versus sham. Abbreviations as in Figure 1.reatment did not reduce them. However, PKC activity is aoupled to its translocation to the outer membrane, and this
as observed after both 3 and 9 weeks of TAC (Fig. 5A).
KC returned to a diffuse distribution consistent with
educed activation after SIL treatment. Confocal analysis
as confirmed by cell fractionation/immunoblot analysis
Fig. 5B). To test whether SIL directly targeted PKC
ctivation, freshly isolated cardiomyocytes were incubated
ith the PKC activator PMA; PMA induced rapid PKC
embrane translocation (Fig. 5C) but SIL coincubation did
ot suppress it, suggesting that the in vivo effect was more
ikely indirect.
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Sildenafil and Advanced Hypertrophic Heart Disease January 13, 2009:207–15f morbidity and mortality worldwide, and new approaches
o combat this pathophysiology are needed. In a prior study,
e first showed that PDE5A inhibition coupled with
ctivation of PKG may offer a novel approach to treating
his disorder (8). The present results substantially extend
his finding. First, therapy was initiated only after the
ypertrophic disease process was far more established, yet
mprovements in function, remodeling, and molecular sig-
aling were achieved. Second, isolated myocytes were stud-
ed, revealing enhanced myocyte contraction/relaxation and
a2 handling under both rest and beta-adrenergic receptor
timulated conditions. Third, we extended prior mechanis-
ic analysis, showing improvement of SR calcium handling
roteins coupled with suppression of both Cn and PKC
ctivation. These findings further support a translational
otential for PDE5A inhibitors in established hypertrophic
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yme. Their role in physiologic cardiac cGMP regulation
emains largely unknown. The first selective cGMP-PDE
iscovered was PDE5A, and it remains the best character-
zed (5). Although first thought to have little role in the
eart, growing evidence supports its regulation of a localized
GMP pool that can potently modulate cardiac stress
esponses (5–8), and the current data strongly supports this
urther.
Hydrolysis of cGMP by PDE5A is compartmentalized
nd seems to particularly target NOS-generated cGMP
9,10,24). However, sustained pressure overload results in
unctional NOS uncoupling, reducing its synthesis of NO
nd increasing its generation of superoxide (14). The fact
hat SIL remains effective in such a setting is important and
ay relate to observations that PDE5A inhibition reduces
O-reactive oxygen species interaction decline in nitroty-
osine and improves NOS coupling and activity in TAC
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Sildenafil and Advanced Hypertrophic Heart Disease January 13, 2009:207–15hronic positive contractility responses shares some similar-
ty to -blockade. Acute -blockade is negatively inotropic,
ut this effect depends on the level of adrenergic tone,
hereas chronic blockade in a stressed/failing heart en-
ances contraction, likely by suppressing sustained catechol-
mine cytotoxicity (27). However, -blockers are far less
otent in suppressing pressure overload hypertrophy and
heir utility in hypertensive heart disease has been ques-
ioned (28). By contrast, PDE5A inhibitors target more
istal signaling and suppress hypertrophy and maladaptive
olecular changes triggered by mechanical and neurohu-
oral stress even without altering blood pressure. By block-
ng pathways that otherwise depress Ca2 handling, myo-
yte function, and remodeling, the net chronic effect
ositively impacts contractility.
Our results contrast to those of a recent study performed
n chronic right ventricular hypertrophied rat hearts, in
hich PDE5A inhibition acutely augmented contractility
inked to an increase in cAMP (not cGMP) and activation
f protein kinase A (not PKG) (29). In this study, myocyte
hortening was equally enhanced by isoproterenol, SIL, or
heir combination, suggesting that the same pathway was
ctivated by both. Right ventricular hypertrophy reduced
KG activity (and phosphorylated VASP) and increased
DE5A expression. In contrast, we found that ISO aug-
ented LV myocyte shortening similarly in mice subjected
o TAC  SIL, hypertrophy enhanced PKG activity (and
VASP) and SIL increased it further, and PDE5A expres-
ion was unchanged. In our prior study, myocardial cAMP
as also similar in hearts subjected to chronic TAC  SIL
8). The difference may lie between chronic versus acute
nterventions, right versus left ventricle, or conceivably
pecies. With regard to the latter, PDE5A inhibitors blunt
-adrenergic stimulation in humans(26) similar to their
ffect in mice(10).
DE5A inhibition and calcium cycling regulation. Sil-
enafil acutely depresses ISO-stimulated contraction with-
ut altering the whole cell Ca2 transient (10). This may
eflect a balance between a PKG-mediated decline in
-type Ca2 current (30), reduced myofilament sensitivity
31), and PLB phosphorylation (32). With chronic pressure
verload, however, other regulators seem involved. Reduced
LB phosphorylation is found in experimental and human
eart failure (32), and both Cn and PKC are thought play
role. PKC is the dominant isoenzyme in heart and
ranslocates to the outer sarcolemmal membrane on stimu-
ation (33). It phosphorylates and thus inhibits I-1 (inhib-
tor of the phosphatase PP1), reducing PLB phosphoryla-
ion. Genetic (19) and pharmacologic (34) blockade of
KC improves function, although its impact on hypertro-
hy is less marked. Whereas SIL did not alter PKC (or
ther PKC isoforms) protein expression, it shifted it away
rom the outer membrane consistent with de-activation.
lso, I-1 can be inhibited by Cn via dephosphorylating sites
ormally stimulated by PKA (Thr-35) (17,35). Futuretudies are needed to directly prove the role of I-1 modu-
ation to SIL-modified cardiac function.
onclusions
elayed SIL treatment inhibits the progression of hyper-
rophy, fibrosis, and chamber remodeling, and improves
asal and -stimulated contractility and relaxation in a
odel of established pressure overload–induced hypertro-
hic heart disease. Functional improvement is coupled to
nhanced Ca2 handling, and increased expression of SR
a2 uptake proteins and PLB phosphorylation likely
ontribute. The capacity of SIL to block maladaptive
emodeling even when administered later in the disease
rocess provides important experimental support for current
linical studies, where disease will already be present.
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APPENDIX
or a supplementary Methods section and a figure showing calcineurin
rotein expression and activity increase after 3 weeks of transaortic
onstriction, please see the online version of this article.
